Renal transplantation has excited both physicians and patients for more than 30 years. The role of transplantation in the treatment of renal failure was not firmly established until the early 1960s, after the introduction of the immunosuppressive agents azathioprine and prednisone [17] and, somewhat later, antilymphocyte globulin (AI_G) preparations [t8] . With the advent of cyclosporine in the late 1970s and early 1980s [2] , renal transplantation expanded greatly. At present, 1-year patient survivals of > 9 0 % and graft survivals of 80% for cadaveric allografts are not uncommon [14] . However, even with these improved results, some patients lose their grafts to rejection. Ideally, the goal is complete patient and graft survival with a very low incidence of morbidity. Many of the concerns of the early 1960s remain: donor organ preservation, immunosuppression, rejection, sensitization, infection, and issues related to organ supply and distribution. These problems are discussed, and some of the more recent developments and their implications for the clinical renal transplant surgeon are pointed out.
Organ preservation
Donor organ preservation has recently benefited from a major new advance. Historically, cold storage with relatively high osmotic preservation fluids (i.e., modified Col- lin's solution) has been the generally accepted mode of preservation [4] . The ultimate renal function of organs kept in this manner was as good as that of organs preserved with pulsatile perfusion storage, without the cost or inconvenience required for the latter [4] . The incidence of delayed graft function, primary nonfunction, and graft failure increases exponentially with the duration of cold storage [21] . Belzer's group at the University of Wisconsin (UW) has achieved a quantum improvement in static cold preservation of the kidneys and, especially, of the liver and pancreas (Table 1 ) [1] . The addition of lactobionate and hydroxyethyl starch has been shown to control intracellular fluid and electrolyte shifts in the donor organ [1] . The solution appears to stabilize cell membranes during cold storage and at the time of reperfusion [1] . The results of these authors in canine renal transplants suggest that cold storage for up to 5 days is possible [1] .
Preservation injury is thought to have two components. The first is produced by ischemia, with which cellular energy reserves decay to the point that synthetic functions required for cellular integrity are no longer adequate. The second component of preservation injury is thought to occur during reperfusion, when the blood supply to the donor organ is reestablished. Evidence suggests that this type of injury is produced by oxygen free radicals [11] . These radicals are generated by the breakdown of ATP by xanthine oxidase during the initial phases of reperfusion. When hypoxanthine, molecular oxygen, and water are combined in the presence of xanthine oxidase, oxygen is reduced to a superoxide free radical [11] . Under ischemic conditions, xanthine oxidase replaces xanthine dehydrogenase as the major enzyme in the degradation of ATP to AMP and adenosine and of inosine to hypoxanthine [11] . An experimental study in pigs has shown that pretreatment of the transplanted kidney with either superoxide dismutase (SOD) or allopurinol (xanthine oxidase inhibitor) significantly improves kidney function ( Fig. 1 ) [6] . The results support the hypothesis that the production of oxygen free radicals during reperfusion may contribute to delayed graft function. A multicenter, prospective, randomized clinical trial evaluating recombinant human SOD (Pharmacia) in cadaveric renal transplantation, coordinated by the University of Pittsburgh, will begin on July 1, 1988. Furthermore, recent porcine studies from our laboratory, which mirror the clinical transplant situation, have demonstrated a significant improvement in kidney function when human recombinant SOD is given at relatively high doses prior to the revascularization of 24-h cold-preserved kidneys (manuscript in preparation). 137 rate; (b) direct toxicity ot the endothelial, glomerular, and tubular cells; (c) aberration of the renin-angiotensin system; and (d) alterations in arachidonic acid metabolism with local microcirculatory effects [5] .
A variety of effects of cyclosporine on the eicosanoid metabolism in renal tissues have been studied. These results suggest alterations in the production of thromboxane AE, prostaglandin E z, and prostacyclin [5, 8, 15] . Recent evidence has shown that thromboxane AE production is stimulated in rodent cyclosporine nephrotoxicity models [15] . It has also been shown that the addition of exogenous prostaglandin E2 reduces the incidence of cyclosporine nephrotoxicity in rats [8] . Clinical studies with thromboxane A 2 inhibitors in patients with presumed cyclosporine nephrotoxicity are in progress.
The real problems with cyclosporine have led to the continued search for new immunosuppressive agents; FK 506 is one of the most promising. This drug has demonstrated extraordinarily potent immunosuppressive activity in animal models (Figs. 2, 3 ) [20] . A summary of the pharmacology in in vitro and animal studies involving FK 506 was presented at a satellite meeting of the European Society for Organ Transplantation in Gothenburg, Sweden, in 1987. Phase I-II clinical trials with this agent are currently being planned. Deoxyspergualin is another new immunosuppressive agent that has been widely studied in animals [24] .
Lymphocyte-mediated rejection is a major factor in kidney loss. There has been much progress in the area of antilymphocyte globulin (ALG). The progression from the original polyclonal preparations ALG and antithymocyte globulin (ATG) to the more sophisticated monoclonal counterpart OKT3 (Orthoclone, Ortho Pharmaceutical) results in greater target selectivity. Even more selectivity has been achieved by the development of monoclonal antibodies to the IL-2 receptor as well as to the CD4, C D l l , and CD12 antigens [22, 26] .
DNA hybridization technology has been used to fashion a gene that produces a fusion protein consisting of a diphtheria toxin with a moiety that binds to IL-2 receptors [7] . The IL-2 portion fixes the protein to the Tlymphocyte, and the diphtheria portion kills the ceil. Most of these new approaches are still at a preclinical stage.
Immunosuppression
The cyclosporine era is now in its 8th year. There is no doubt that cyclosporine has had a major impact on the transplantation of not only kidneys but also extrarenal organs. Most centers now report a l-year graft survival > 75070 and as high as 90070 in cadaveric renal transplants [14] . However, cyclosporine is not without its hazards. Cyclosporine's main side effect and limiting feature is nephrotoxicity, which may occur in as many as 80070 of patients [5] . Studies of cyclosporine nephrotoxicity have suggested four possible mechanisms of injury: (a) a reduction in renal blood flow and glomerular filtration
The highly sensitized state
The driving force behind the development of new immunosuppressive agents and polypharmaceutical treatment protocols is the continuing failure of transplantation in certain specific groups of patients. One of the greatest problems exists in those patients sensitized by previous transplants, transfusions, or pregnancy. Patients who have preformed antibodies to a panel of lymphocytes obtained from the general population are considered to be presensitized. Such patients with a presensitized rate (Panel Reactive Antibodies, PRA) >40070 have significantly worse graft survival. In addition, there that involves every arm of the inflammatory response, with the release of a multitude of biologically active mediators and with numerous cellular events that finally lead to microcirculatory failure and ischemic necrosis of the organ. New concepts in the pathophysiology of this process have considered the importance of vasoconstriction as a primary event and the release of platelet-activating factor (PAF) as one of the central mediators of this process [9] . Thus, the future management of hyperacute rejection will certainly involve the use of potent vasodilators and antagonists of such mediators as PAE In fact, we have demonstrated a beneficial effect of a potent PAF antagonist, SRI 63-441 + PGI2 or PGE 1, on hyperacute rejection in a xenograft model of pig-to-dog renal transplantation (Fig. 4 ) and in a model of heterotropic cardiac transplantation in rats presensitized by multiple serial skin grafts [10] . is a more puzzling group of patients whose presensitized rate is low, yet who aggressively reject an allograft. To maximize graft survival in such patients, some centers have adopted a policy of transplanting organs into the best recipients, namely, those who are young and healthy, with low PRAs. The difficulty with this approach is that it denies transplantation to a large group of potential recipients, who do not meet these restrictive requirements.
A new development that may benefit such patients involves the use of specific IgG and IgM depletion by passing plasma over a column containing the staphylococcus A exotoxin, which binds to the IgG Fc receptor. A reduction of up to 90°70 in IgG levels can thus be obtained [12] . A preliminary trial in Europe has used this new technology to transplant highly sensitized patients [12] . The ability to overcome successfully the hypersensitized state will have important implications for xenograft transplantation, which is currently most hampered by the presence of preformed xenoantibodies. Furthermore, it is known that once these antibodies bind to antigens on the endothelium of the xenograft, a whole cascade is initiated Although improvements have been made in renal transplantation, infection remains a significant cause of morbidity and mortality; the causes of infection include protozoal, viral, fungal, and bacterial organisms. Some of these infections can be prevented by low doses of drugs effective against specific pathogens. For example, oral mycostatin reduces candida infections in the gastrointestinal tract, and low doses of trimethoprim-sulfamethoxazole greatly reduces the incidence of P n e u m o c y s t i s carinii pneumonia. Cutaneous herpes infections can be prevented by low-dose acyclovir therapy, but the more serious cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections are more difficult to prevent. The anti-CMV drug, D H P G (Ganciclovir, Syntex), has shown great promise in early trials but is still experimental [13] . IV human immunoglobulin preparations have been used to confer passive immunity. Many studies suggest successful prophylaxis and possible treatment for CMV and EBV infections using such immunoglobulin preparations PGI2 ). Results are expressed as total survival time (mean min_SE) (reprinted from [9] with permission) [3] . The exact role of prophylactic IV human immunoglobulin with or without D H P G administration in the management of transplant-associated infections has yet to be determined.
Organ supply and distribution
Historically, the rate-limiting step in transplantation has been the number of available donor organs, and waiting lists continue to expand as the number of potential recipients exceeds the number of donors. Two developments have occurred that address this problem. The first deals with the supply of donors. Living related donors have been an important source of kidneys in several programs. The use of living unrelated donors has recently been attempted, with reasonable results [16] ; these were generally spousal donors. Although somewhat controversial and involving numerous ethical implications, this approach may play a role in alleviating the donor shortage. The second development in the United States has been the establishment of a system of organ allocation that guarantees equal access to recipients: it gives priority to presensitization and time on the waiting list and assigns points accordingly. Recipients of a given kidney are selected by this point system, which was initially described at the University of Pittsburgh and has since been adopted by UNOS (United Network of Organ Sharing) [19] . Although these criteria for organ allocation will certainly undergo future modifications, they nonetheless represent a first attempt at an orderly, coordinated, and well-organized method for organ sharing.
